Department of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People's Republic of China.
Department of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People's Republic of China.
Acta Biomater. 2015 Jan;11:191-203. doi: 10.1016/j.actbio.2014.09.030. Epub 2014 Sep 23.
Adipose-derived stem cells (ADSCs) are promising for cartilage repair due to their easy accessibility and chondrogenic potential. Although chondrogenesis of transforming growth factor-β (TGF-β) mediated mesenchymal stem cells (MSCs) is well established in vitro, clinical tissue engineering requires effective and controlled delivery of TGF-β in vivo. In this work, a self-assembled peptide scaffold was employed to construct cartilages in vivo through the chondrogenesis from ADSCs controlled by recombinant fusion protein LAP-MMP-mTGF-β3 that was transfected by lentiviral vectors. During this course, the addition of matrix metalloproteinases (MMPs) can trigger the release of mTGF-β3 from the recombinant fusion protein of LAP-MMP-mTGF-β3 in the combined scaffolds, thus stimulating the differentiation of ADSCs into chondrogenesis. The specific expression of cartilage genes was analyzed by real-time polymerase chain reaction and Western blot. The expression of chondrocytic markers was obviously upregulated to a higher level compared to the one by commonly used TGF-β3 alone. After 3 weeks of in vitro culturing, the hybrids with differentiated chondrogenesis were then injected subcutaneously into nude mice and retrieved after 4 weeks of culturing in vivo. Histological analysis also confirmed that the recombinant fusion protein was more effective for the formation of cartilage matrix than the cases either with TGF-β3 alone or without LAP-MMP-mTGF-β3 (P<0.05). This study demonstrates that controlled local delivery of the LAP-MMP-mTGF-β3 constructs can accelerate differentiation of ADSCs into the cartilage in vivo, which indicates the great potential of this hybrid in rapid therapy of osteoarthritis.
脂肪来源的干细胞(ADSCs)因其易于获取和软骨生成潜力而在软骨修复中具有广阔的应用前景。尽管转化生长因子-β(TGF-β)介导的间充质干细胞(MSCs)的软骨生成在体外已经得到充分证实,但临床组织工程需要在体内有效且受控地递送达 TGF-β。在这项工作中,我们使用自组装肽支架通过转染慢病毒载体的重组融合蛋白 LAP-MMP-mTGF-β3 控制 ADSCs 的软骨生成,从而在体内构建软骨。在此过程中,基质金属蛋白酶(MMPs)的添加可以触发 LAP-MMP-mTGF-β3 重组融合蛋白从复合支架中释放 mTGF-β3,从而刺激 ADSCs 向软骨分化。通过实时聚合酶链反应和 Western blot 分析软骨基因的特异性表达。与单独使用 TGF-β3 相比,细胞外基质标志物的表达明显上调到更高水平。在体外培养 3 周后,将分化为软骨的杂交物皮下注射到裸鼠中,并在体内培养 4 周后取回。组织学分析也证实,与单独使用 TGF-β3 或不使用 LAP-MMP-mTGF-β3 的情况相比,重组融合蛋白更有利于软骨基质的形成(P<0.05)。这项研究表明,LAP-MMP-mTGF-β3 构建物的局部控释可以加速 ADSCs 在体内向软骨的分化,这表明该杂交物在骨关节炎的快速治疗中具有巨大的潜力。